Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Daniel Cimbora"'
Autor:
Ho Jin Kim, Orhan Aktas, Kristina R. Patterson, Schaun Korff, Amy Kunchok, Jeffrey L. Bennett, Brian G. Weinshenker, Friedemann Paul, Hans‐Peter Hartung, Daniel Cimbora, Michael A. Smith, Nanette Mittereder, William A. Rees, Dewei She, Bruce A. C. Cree
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 10, Iss 12, Pp 2413-2420 (2023)
Abstract Inebilizumab, a humanized, glycoengineered, IgG1 monoclonal antibody that depletes CD19+ B‐cells, is approved to treat aquaporin 4 (AQP4) IgG‐seropositive neuromyelitis optica spectrum disorder (NMOSD). Inebilizumab is afucosylated and e
Externí odkaz:
https://doaj.org/article/117e79e5e7134a03b6b3f3c65a13a5f5
Autor:
Cory Perugino, Emma L. Culver, Arezou Khosroshahi, Wen Zhang, Emanuel Della-Torre, Kazuichi Okazaki, Yoshiya Tanaka, Matthias Löhr, Nicolas Schleinitz, Judith Falloon, Dewei She, Daniel Cimbora, John H. Stone
Publikováno v:
Rheumatology and Therapy, Vol 10, Iss 6, Pp 1795-1808 (2023)
Abstract Introduction Immunoglobulin G4-related disease (IgG4-RD) is a debilitating multiorgan disease characterized by recurring flares leading to organ dysfunction, decreased quality of life, and mortality. Glucocorticoids, the standard of care for
Externí odkaz:
https://doaj.org/article/8fd489c2c4564ecf821166afa716dc2e
Autor:
Jeffrey L. Bennett, Orhan Aktas, William A. Rees, Michael A. Smith, Michele Gunsior, Li Yan, Dewei She, Daniel Cimbora, Sean J. Pittock, Brian G. Weinshenker, Friedemann Paul, Romain Marignier, Dean Wingerchuk, Gary Cutter, Ari Green, Hans-Peter Hartung, Ho Jin Kim, Kazuo Fujihara, Michael Levy, Eliezer Katz, Bruce A.C. Cree
Publikováno v:
EBioMedicine, Vol 86, Iss , Pp 104321- (2022)
Summary: Background: Inebilizumab is an anti-CD19 antibody approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults with aquaporin-4 autoantibodies. The relationship between B-cell, plasma-cell (PC), and immunoglobulin d
Externí odkaz:
https://doaj.org/article/790df91e946941298837a5937869bc85
Autor:
Friedemann Paul, Roman Marignier, John Lindsey, Ho Jin Kim, Dewei She, Daniel Cimbora, Kristina Patterson, Bruce Cree
Publikováno v:
Thursday, April 27.
Autor:
Dewei She, Eliezer Katz, Aram Zabeti, Maureen A. Mealy, Jorn Drappa, Daniel Cimbora, Mary Rensel
Publikováno v:
Multiple Sclerosis Journal. 28:925-932
Background: Efficacy and safety of inebilizumab for treatment of neuromyelitis optica spectrum disorder in adults seropositive for aquaporin-4 (AQP4)–immunoglobulin (Ig) G were demonstrated in the 28-week randomized controlled period of the N-MOmen
Autor:
Orhan Aktas, Hans-Peter Hartung, Michael A Smith, William A Rees, Kazuo Fujihara, Friedemann Paul, Romain Marignier, Jeffrey L Bennett, Ho Jin Kim, Brian G Weinshenker, Sean J Pittock, Dean M Wingerchuk, Gary Cutter, Dewei She, Michele Gunsior, Daniel Cimbora, Eliezer Katz, Bruce A Cree
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. :jnnp-2022
ObjectiveTo investigate relationships between serum neurofilament light chain (sNfL), ubiquitin C-terminal hydrolase L1 (sUCHL1), tau (sTau) and glial fibrillary acidic protein (sGFAP) levels and disease activity/disability in neuromyelitis optica sp
Autor:
Li Yan, Bing Wang, Dewei She, Ben Mitchell, Ryan Criste, Daniel Cimbora, Eliezer Katz, William A. Rees
AIM: Neuromyelitis optica spectrum disorders (NMOSD) is an autoantibody-mediated, B cell-driven disease. Inebilizumab is a humanized, affinity-optimized, afucosylated IgG1 kappa monoclonal antibody that binds to the B cell specific surface antigen CD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2c01de72e414a730acfbf5d4ed29745
https://doi.org/10.22541/au.163676321.19163981/v1
https://doi.org/10.22541/au.163676321.19163981/v1
Publikováno v:
Clinical pharmacokinetics. 61(3)
Background and objective Inebilizumab is a humanized, affinity-optimized, afucosylated immunoglobulin (Ig)-G1κ monoclonal antibody that binds to CD19, resulting in effective depletion of peripheral B cells. It is being developed to treat various aut
Autor:
John N. Ratchford, Romain Marignier, F. Paul, Dewei She, Ian M. Williams, Orhan Aktas, Ari J. Green, Brian G. Weinshenker, Sean J. Pittock, Jorn Drappa, Daniel Cimbora, Eliezer Katz, Hans-Peter Hartung, Fred D. Lublin, Michael E. Smith, Ho Jin Kim, Gary R. Cutter, Dean Wingerchuk, Jeffrey Bennett, William Rees, Kazuko Fujihara, Bruce A.C. Cree
Publikováno v:
Neurology® Neuroimmunology & Neuroinflammation
article-version (Version of Record) 3
article-version (Version of Record) 3
ObjectiveTo assess treatment effects on Expanded Disability Status Scale (EDSS) score worsening and modified Rankin Scale (mRS) scores in the N-MOmentum trial of inebilizumab, a humanized anti-CD19 monoclonal antibody, in participants with neuromyeli
Autor:
Friedemann Paul, Ari J. Green, John N. Ratchford, Brian G. Weinshenker, Dewei She, Sean J. Pittock, Orhan Aktas, Ho Jin Kim, Hans-Peter Hartung, Romain Marignier, Jorn Drappa, Jeffrey Bennett, Eliezer Katz, Dean M. Wingerchuk, Daniel Cimbora, Kazuo Fujihara, Bruce A.C. Cree, Gary Cutter, Michael E. Smith, William Rees
Publikováno v:
Multiple Sclerosis and Related Disorders. 57:103356
Background The N-MOmentum trial, a double-blind, randomized, placebo-controlled, phase 2/3 study of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD), enrolled participants who were aquaporin-4-immunoglobulin G (AQP4-IgG)-seropositive (A